Literature DB >> 11005467

The current role of thrombolytic therapy for pulmonary embolism.

S Z Goldhaber1.   

Abstract

Thrombolytic therapy for pulmonary embolism can rapidly reverse right ventricular failure and reduce mortality and morbidity among appropriately selected patients. Individuals being considered for this treatment should be screened for potential major bleeding problems, which, if present, should lead to alternative management with catheter or surgical embolectomy. There is no ideal thrombolytic agent; nor have indications for thrombolysis been precisely defined. Available data indicate that patients with moderate or severe right ventricular dysfunction gain the most from this pharmacologic strategy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005467

Source DB:  PubMed          Journal:  Semin Vasc Surg        ISSN: 0895-7967            Impact factor:   1.000


  2 in total

1.  Virchow's Legacy: deep vein thrombosis and pulmonary embolism.

Authors:  Jorge Cervantes; Guillermo Rojas
Journal:  World J Surg       Date:  2005       Impact factor: 3.352

2.  High dose and short-term streptokinase infusion in patients with pulmonary embolism: prospective with seven-year follow-up trial.

Authors:  C Jerjes-Sanchez; A Ramirez-Rivera; R Arriaga-Nava; S Iglesias-Gonzalez; P Gutierrez; C Ibarra-Perez; A Martinez; S Valencia; A Rosado-Buzzo; J A Pierzo; E Rosas
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.